Navigation path


Impact of Specific Antibiotic Therapies on the prevalence of hUman host ResistaNt bacteria
EC contribution
: € 5,999,436
: 60 months
Starting date
: 01/01/2010
Funding scheme
: Focused Research Project
: Antimicrobial resistance; Antibiotic resistant bacteria; Pharmacokinetics; Pharmacodynamics; Microbiology; Bacterial Genetics; Epidemiology; Therapeutic drug use
Contract/Grant agreement number :
: 241796
Project web-site


SATURN will study the impact of antibiotic exposure on antimicrobial resistance (AMR) with a multidisciplinary approach that bridges microbiological, clinical, epidemiological and pharmacological research. SATURN will improve methodological standards and conduct research to better understand the impact of antibiotic use on acquisition, selection and transmission of antibiotic-resistant bacteria (ARB) in different environments, by combining state-of-the-art analyses of molecular, ecologic and individual patient-level data. The proposed program and anticipated results will help reduce the burden of AMR in Europe and guide both clinical decision making and policy decisions in this area.


SATURN responds to an urgent need, as stated in the EU Council conclusions (June 2008) on AMR, in which the EU stresses the need of research in the area of AMR, e.g. to increase the understanding of the mechanisms and underlying risk factors that advance the development of AMR and to increase the knowledge of the effectiveness of current and future control measures. AMR is rampant among bacteria that cause healthcare- and community-acquired infections, driving up costs and increasing the difficulty of therapeutic management. To gain a handle on the factors that are propelling the problem of AMR, molecular and patient-level investigations are necessary to better elucidate the time-varying and heterogeneous role of antibiotic selection pressure on emergence and selection of AMR.

[+] Read More